Arecor Limited (“Arecor” or “the Company”), the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that it has signed a further collaboration with a major global pharmaceutical company.
Under this new agreement, Arecor will use its proprietary formulation technology platform Arestat™ to develop a differentiated, thermostable liquid formulation of one of the global pharmaceutical company’s key proprietary products. The new formulation will be stored at room temperature to improve the ease of use of the product by healthcare providers and patients, whilst also simplifying the supply chain. The pharmaceutical company will fund the development work and has the option to acquire the rights to the new proprietary formulation and associated Intellectual Property under a technology licensing model.
Sarah Howell, Chief Executive Officer at Arecor, said: "This additional collaboration with an existing partner further demonstrates the value of our innovative, Arestat™ technology platform. We are focused on leveraging ArestatTM to deliver superior reformulations of key products that can improve patient care as well as add commercial value to our partners. This new agreement validates both the commercial value of Arestat™, and the strength and breadth of our scientific reformulation and development expertise.”
About Arecor (www.arecor.com)
Arecor Limited is a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products that will enable improved treatments for diabetes via the innovative reformulation of approved proteins and peptides. Arecor's product portfolio also includes:
• Novel insulin formulations to deliver ultra-rapid acting insulin analogs and;
• Ultra-concentrated rapid acting insulin to enable the miniaturisation of devices,
• Stable aqueous glucagon for emergency and artificial pancreas use, and
• A series of undisclosed pre-clinical programmes.
In addition, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.
Arecor Limited (www.arecor.com)
Dr Sarah Howell, Chief Executive Officer
Tel: +44 (0) 1223 426060
Susan Lowther, Chief Financial Officer
Tel: +44 (0) 1223 426060
Mo PR Advisory (www.mopradvisory.com)
Mob: +44 (0) 7876 444977